Synthetic Biologics' SYN-004 (Ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for Clostridium difficile Infection.
- Published in:
- Clinical Infectious Diseases, 2017, v. 64, n. 8, p. i, doi. 10.1093/cid/cix161
- By:
- Publication type:
- Article
Works matching DE "SYNTHETIC Biologics Inc."
Results: 2
1
2
People.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 6, p. 566, doi. 10.1038/nbt.2271
- Publication type:
- Article